Bruce N. Jacobs, Chief Financial Officer at Kymera Therapeutics, Inc. (KYMR), sold 1,370 shares at $30.88 ($42K) on 2023-03-02, disclosed to the SEC on 2023-03-03.
Scheduled sale ($42k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.88 | 1,056 | $33K | 76.8% |
| 2 | $31.40 | 314 | $10K | 23.2% |
| Total | $31.00 avg | 1,370 | $42K | 100% |
| Filing → |
| KYMR | SELL | 2025-09-17 | $4.0M | — | Filing → |
| KYMR | SELL | 2025-03-03 | $389K | — | Filing → |
| KYMR | SELL | 2024-03-04 | $318K | — | Filing → |